Description
+ Include: 222 videos + 1 pdf, size: 79.6 GB
+ Target Audience: hematologist, oncologist
+ Sample video: contact me for sample video
+ Information:
Virtual Meeting
19 – 23 March, 2022
Annual Meeting Congress Co-Presidents: Pavel Jindra and Petr Sedláček
Scientific Chair: Edgar Faber
Local Nurse Chair: Klára Kabátová Maxová
The 48th Annual Meeting of the EBMT had switch to a fully virtual format instead of a hybrid one at the very last minute. This year’s meeting meant that it has been our 3rd consecutive virtual Annual Meeting in a row. Although this last-minute change was absolutely justified because of the unprecedented humanitarian crisis in Ukraine, none of us could hide our disappointment. we were all looking forward to going to Prague and reconnecting with each other in-person after two long and complicated years due to COVID-19 pandemics.
But, in spite of all these hurdles, I am very proud and happy to say that this edition which took place one month ago was a big success and a clear demonstration of the commitment of all the various individuals involved in making the 48th Annual Meeting of the EBMT, the best in its class. I would also like to give a big thank you to Petr Sedlacek and Pavel Jindra for their enthusiasm, flexibility and continuous dedication to this year’s meeting, to the speakers and chairs for their flexibility and understanding, to the pharmaceutical sponsors for their rapidness in accommodating their educational activities to the virtual format and last, but not least, to the EBMT staff that made it all possible.
There were more than 5,000 attendees signed up this year coming from more than 90 countries and almost 500 speakers and chairs from more than 30 countries were able to deliver more than 700 presentations. The feedback we have received has been excellent so far. Despite the fact that we were not able to see each other, we did get to enjoy a cutting-edge scientific programme in a friendly user technological environment and I hope all of you have enjoyed the event it as much as I have.
Finally, a special thank you from my side goes out to Nicolaus Kröger, Mohamad Mohty, Christian Chabannon and Ibrahim Yacoub-Agha for their excellent work and commitment to EBMT during their mandate and congratulations to Fabio Ciceri, Annalisa Ruggeri and Donal McLornan for being elected as the new EBMT Working Party Chairs of the Acute Leukaemia, Cellular Therapy & Immunobiology and Chronic Malignancies Working Parties. I am looking forward to working with all of you.
+ Topics:
Mar 19 Apheresis Access challenges.mp4
Mar 19 Apheresis Management of side effects.mp4
Mar 19 Apheresis Mobilization in stem cell donors- the basics and points of attention.mp4
Mar 19 Best abstract awards.mp4
Mar 19 Cellular Therapy beyond CAR T and HSCT DLI Donor Lymphocyte Infusion How it works and indications.mp4
Mar 19 Cellular Therapy beyond CAR T and HSCT NK cells and dendritic cells as tool for immunotherapy.mp4
Mar 19 Cellular Therapy beyond CAR T and HSCT Treatment of viral infection with T-Cell (Adoptive immunotherapies).mp4
Mar 19 COVID Transplant care in the post pandemic era.mp4
Mar 19 COVID Vaccination in transplant population.mp4
Mar 19 COVID Workforce wellbeing.mp4
Mar 19 COVID-19 Introduction.mp4
Mar 19 COVID-19 Prevention policies, measures and testing in the setting of allogeneic HCT.mp4
Mar 19 COVID-19 SARS-COV-2 vaccines for HCT recipients.mp4
Mar 19 COVID-19 Treatment of COVID19 after HCT.mp4
Mar 19 Data Management Session 1.mp4
Mar 19 Data Management Session 2 CT Discussion Forum.mp4
Mar 19 Data Management Session 3.mp4
Mar 19 Data Management Session 4.mp4
Mar 19 Difficult conversations around blood and marrow transplantation.mp4
Mar 19 EBMT-WMDA Transplant and Search Coordinators Day A unique phenotype what do I do.mp4
Mar 19 EBMT-WMDA Transplant and Search Coordinators Day Emerging challenges in donor identification and selection.mp4
Mar 19 EBMT-WMDA Transplant and Search Coordinators Day Lessons to share.mp4
Mar 19 Global Committee Session Conclusions.mp4
Mar 19 Global Committee Session Global evolution of CAR T cells Acute T lymphoblastic leukemia as a model.mp4
Mar 19 Global Committee Session Global evolution The future of allogeneic stem cell transplantation the next decade.mp4
Mar 19 Global Committee Session Global evolution The future of fecal microbiotome transplantation.mp4
Mar 19 Global Committee Session Introduction.mp4
Mar 19 Global Committee Session Navigating the road ahead for the implementation of novel Cell-based Therapies worldwide.mp4
Mar 19 Global Committee Session Remodeling clinical care for stem cell transplantation in a post pandemic world.mp4
Mar 19 GVHD practical tips GVHD and the eye update on diagnosis and management of – ocular GVHD.mp4
Mar 19 GVHD practical tips Mouth.mp4
Mar 19 GVHD practical tips Skin.mp4
Mar 19 GVHD treatment and supportive care Eating well with GVHD.mp4
Mar 19 GVHD treatment and supportive care Physiotherapy guidelines for managing patients undergoing hematopoietic stem cell transplantation.mp4
Mar 19 GVHD treatment and supportive care Supportive care in GVHD.mp4
Mar 19 HLA Beyond the simple allele counting HLA and mechanism of relapse.mp4
Mar 19 HLA Beyond the simple allele counting HLA-DP matching and expression as tool for donor selection refinement.mp4
Mar 19 HLA Beyond the simple allele counting Introduction.mp4
Mar 19 HLA Beyond the simple allele counting New concepts in the HLA barrier in transplantation.mp4
Mar 19 How Do I… improve SCT outcome in elderly How I select conditioning regimen in elderly patients.mp4
Mar 19 How Do I… improve SCT outcome in elderly HSCT in the Eighth Decade.mp4
Mar 19 How Do I… improve SCT outcome in elderly Q&A.mp4
Mar 19 How Do I… improve SCT outcome in elderly QoL after allogeneic SCT in elderly patients.mp4
Mar 19 How to support caregivers of HSCT patients.mp4
Mar 19 JACIE Inspector’s perspective.mp4
Mar 19 JACIE JACIE What’s new for nurses.mp4
Mar 19 JACIE Nursing considerations and perspective.mp4
Mar 19 Joint Session EBMT-HARMONY Closing message of the HARMONY Patient Cluster in collaboration with the EBMT Patient Committee.mp4
Mar 19 Joint Session EBMT-HARMONY Doing research within the HARMONY Alliance in AML.mp4
Mar 19 Joint Session EBMT-HARMONY Expectancies of the pharmaceutical industry in a successful EBMT.mp4
Mar 19 Joint Session EBMT-HARMONY Introducing the HARMONY Alliance [HARMONY and HARMONY PLUS].mp4
Mar 19 Joint Session EBMT-HARMONY The building of a new EBMT platform.mp4
Mar 19 Joint Session EBMT-HARMONY The HARMONY Machine Learning Researching Tool.mp4
Mar 19 Joint Session EBMT-HARMONY The HARMONY unique data anonymization concept.mp4
Mar 19 Joint Session EBMT-HARMONY What value can Big Data technology add in the daily.mp4
Mar 19 Joint session EBMT-KSBMT European perspective.mp4
Mar 19 Joint session EBMT-KSBMT Optimal selection of Unrelated donor and Cord blood units Korean perspective.mp4
Mar 19 Joint session EBMT-KSBMT Panel Discussion.mp4
Mar 19 Joint session EBMT-WBMT Adapting inpatient and outpatient clinical care.mp4
Mar 19 Joint session EBMT-WBMT Challenges in donor selection and stem cell collection.mp4
Mar 19 Joint session EBMT-WBMT Global perspective on achieving quality for cellular therapy.mp4
Mar 19 Lab Technicians Day Immune monitoring post cell therapy.mp4
Mar 19 Lab Technicians Day Specialised cell processing.mp4
Mar 19 Paediatrics Session Pediatric nurses perception of factors affecting negotiation.mp4
Mar 19 Paediatrics Session The experiences of pain in children during Haematopoietic Stem Cell Transplantation.mp4
Mar 19 Paediatrics Session Virtual reality on CVC management.mp4
Mar 19 Panel discussion Antiinfective prophylaxis.mp4
Mar 19 Panel discussion How to integrate palliative care and blood and marrow.mp4
Mar 19 Patient, Family and Donor Day Being the perfect match.mp4
Mar 19 Patient, Family and Donor Day Living Beyond Bone Marrow Transplantation.mp4
Mar 19 Patient, Family and Donor Day Lunch with Prof. Buchanan & Kate Washington Special Lecture.mp4
Mar 19 Patient, Family and Donor Day New therapies New Hopes.mp4
Mar 19 Patient, Family and Donor Day Registries matter.mp4
Mar 19 Pharmacotherapy.mp4
Mar 19 Psychological issues in hematopoietic stem cell transplantation.mp4
Mar 19 Quality and education.mp4
Mar 19 Quality Management Abstracts session CAN REGULATORY-DRIVEN PROCESS INNOVATION OPEN.mp4
Mar 19 Quality Management Abstracts session DEVELOPMENT OF A NURSING EDUCATION PATHWAY.mp4
Mar 19 Quality Management Abstracts session IMPACT ON DAYS TO TAKE BY CHANGING FROM FRESH.mp4
Mar 19 Quality Management Abstracts session IMPLEMENTATION OF A STANDARDIZED THERAPEUTIC.mp4
Mar 19 Research session 2 Dressings for the central venous catheter to prevent infection.mp4
Mar 19 Research session 2 The exploration of the dysgeusia in patients with allogeneic.mp4
Mar 19 Research session 2 Variation in hydration use after reinfusion of autologous.mp4
Mar 19 Sickle Cell Anaemia Clonal evolution in Sickle Cell Disease.mp4
Mar 19 Sickle Cell Anaemia Gene correction The next generation of gene therapy for Sickle Cell Disease.mp4
Mar 19 Sickle Cell Anaemia Introduction.mp4
Mar 19 Sickle Cell Anaemia Sickle Cell Disease in adults An orphan disease.mp4
Mar 19 Trainees Day – Transplant for Trainees.mp4
Mar 19 Trainees Day EBMT for Trainees.mp4
Mar 19 What nurses need to know about essential transplant medications Anti-fungal medication.mp4
Mar 19 What nurses need to know about essential transplant medications Anti-viral medication.mp4
Mar 19 What nurses need to know about essential transplant medications Immunosuppression.mp4
Mar 19 What nurses need to know about essential transplant medications Management of bacterial infection.mp4
Mar 19 What nurses need to know about essential transplant medications Prophylactic medication.mp4
Mar 19 What nurses need to know about essential transplant medications Steroids.mp4
Mar 20 5 years and counting Building survival in lymphomas with CAR T Gilead-Kite Industry Symposium.mp4
Mar 20 Advances in the management of Hodgkin lymphoma and implications from emerging RWE in consolidation therapy following ASCT Takeda Industry Symposium.mp4
Mar 20 Allogeneic hematopoietic stem cell transplantation for non-malignant haematological disease SFGM-TC- Non profit Symposium.mp4
Mar 20 Cell therapy revolutionary ideas improving todays practices Miltenyi Biotec Industry Symposium.mp4
Mar 20 CMV in HSCT Breaking down barriers to improve patient outcomes MSD Symposium.mp4
Mar 20 Diagnosis and outcomes of HSCT-TMA practical lessons from the experts Alexion Industry Symposium.mp4
Mar 20 GMMG Symposium.mp4
Mar 20 Looking deep into complexities of Multiple Myeloma (MM) How to decide the treatment and measure the outcomes Pfizer Industry Symposium.mp4
Mar 20 Making the most of ASCT in patients with newly-diagnosed multiple myeloma Janssen Industry Symposium.mp4
Mar 20 mRNA technology addressing a spectrum of unmet needs in vulnerable populations Moderna Industry Symposium.mp4
Mar 20 Nurses Education Day 1 Supporting a patient through transplant.mp4
Mar 20 Nurses Education Day 2 Supporting a patient through transplant.mp4
Mar 20 Nurses Education Day 3 Supporting a patient through transplant.mp4
Mar 20 Nurses Education Day 4 Supporting a patient through transplant.mp4
Mar 20 Opening Ceremony.mp4
Mar 20 Optimizing antifungal treatment options Changing epidemiology of breakthrough fungal infections.mp4
Mar 20 Optimizing New Options for the Treatment of Cytomegalovirus in HSCT Recipients Takeda Medscape Industry Symposium.mp4
Mar 20 Real-world data, pharmacoeconomics and treatment combination in GvHD A focus on ECP Therakos Industry Symposium.mp4
Mar 20 Recent advancements in immune therapies for multiple myeloma BMS Industry Symposium.mp4
Mar 20 Role of C3 inhibition in PNH Sobi Industry Symposium.mp4
Mar 20 The evolving CAR T treatment paradigm in lymphoma BMS Industry Symposium.mp4
Mar 20 The latest advances in hematology and stem cell transplantation an update Sorbonne University (ATERHIT) non-profit symposium.mp4
Mar 20 Understanding the Role of the Lectin Pathway of Complement in HSCT-TMA Omeros Industry Symposium.mp4
Mar 20 Unmet needs in GvHD management a new future within reach Novartis Industry Symposium.mp4
Mar 20 What’s new in GVHD in 2022 tackling the unmet needs from prophylaxis to treatment Sanofi Industry Symposium Q&A.mp4
Mar 20 What’s new in GVHD in 2022 tackling the unmet needs from prophylaxis to treatment Sanofi Industry Symposium.mp4
Mar 20 Will transplant continue to be the SoC in R R DLBCL Gilead-Kite Industry Symposium.mp4
Mar 21 AML and allogeneic HCT for whom, how, and when.mp4
Mar 21 Autoimmune Diseases Working Party session.mp4
Mar 21 Autoimmune Diseases.mp4
Mar 21 CAR T cell therapy for leukaemia and lymphoma.mp4
Mar 21 Cell Therapy Day 1 Immune monitoring post therapeutic intervention.mp4
Mar 21 Cell Therapy Day 2 Clinical monitoring post therapeutic intervention.mp4
Mar 21 Cell Therapy Day 3 CoCART updates.mp4
Mar 21 Chronic Malignancies Working Party session.mp4
Mar 21 Cord blood transplantation Do we still need it.mp4
Mar 21 Critical care in HCT recipients.mp4
Mar 21 Current place of cellular therapy in multiple myeloma.mp4
Mar 21 Delivering ECP to every patient Therakos Industry Symposium.mp4
Mar 21 EBMT Talks Best Abstracts.mp4
Mar 21 Equality, Diversity and Inclusion Session.mp4
Mar 21 Here, Now, and Next Perspectives on the role of CAR-T Cell Therapy in Lymphomas Novartis Industry Symposium.mp4
Mar 21 How Do I… best implement CAR T cell therapy in DLBCL From patient eligibility to long term follow up.mp4
Mar 21 How Do I… manage multiple facets of GVHD treatment A focus on ECP.mp4
Mar 21 How Do I… treat chronic GVHD Supported through an unrestricted educational grant by Sanofi.mp4
Mar 21 How to perform alternative donor transplant in non-malignant disease.mp4
Mar 21 Industry Theatre Idecabtagene vicleucel Idecabtagene vicleucel for the treatment of patients.mp4
Mar 21 Infections.mp4
Mar 21 Infectious Diseases Working Party session.mp4
Mar 21 Nurse’s How Do I… best support MM patients in my practice Supported through an unrestricted educational grant by Janssen.mp4
Mar 21 Nurses Programme Opening Session.mp4
Mar 21 Oral session 1 Lymphoma, CLL, and multiple myeloma.mp4
Mar 21 Oral session 2 Inborn errors, immunodeficiency.mp4
Mar 21 Oral session 3 Various diseases myeloproliferative neoplasm and myelodysplastic syndrome.mp4
Mar 21 Oral session Abstract finalists.mp4
Mar 21 Palliative care after BMT.mp4
Mar 21 Patient Advocacy From gaps to bridges The future of patient advocacy in Central and Eastern Europe.mp4
Mar 21 Patient Advocacy The Dilemma Will CAR-T therapy replace BMT What is the real outcome and impact.mp4
Mar 21 Precise medicine in paediatric leukaemia.mp4
Mar 21 Presidential Symposium.mp4
Mar 21 Start your engines is transplant still the heart of the MM treatment circuit Sanofi (Genzyme) Industry Symposium.mp4
Mar 21 Statistics Workshop.mp4
Mar 21 The older patients in HSCT.mp4
Mar 21 Tools for risk stratification of GVHD.mp4
Mar 22 8th Edition of the Standards.mp4
Mar 22 ABC of immune system I.mp4
Mar 22 ABC of immune system II.mp4
Mar 22 Acute Leukaemia Working Party session Advances in ALL therapy.mp4
Mar 22 Autologous immune cells in cellular therapy.mp4
Mar 22 Biology and treatment of acute GVHD.mp4
Mar 22 Biology and treatment of chronic GVHD.mp4
Mar 22 Boot camp on Accreditation for IEC.mp4
Mar 22 Can we limit infectious complications in transplant setting.mp4
Mar 22 Cellular Therapy and lmmunobiology Working Party session.mp4
Mar 22 Center’s Session.mp4
Mar 22 Disease management.mp4
Mar 22 Does achievement of MRD-negative disease after HSCT improve survival.mp4
Mar 22 General Assembly.mp4
Mar 22 How Do I… conduct effective differential diagnosis of VOD from other post-HSCT complications.mp4
Mar 22 How do I… Understand blood counts.mp4
Mar 22 Inborn Errors Oral Session.mp4
Mar 22 Inborn Errors Working Party session.mp4
Mar 22 Industry Theatre Making a difference for people living with PNH.mp4
Mar 22 Inspectors Session.mp4
Mar 22 Joint session EBMT – ASTCT – CIBMTR – APBMT – LABMT Access to novel cell therapies such as CAR T Cells challenges and strategies.mp4
Mar 22 Kites commitment to manufacturing excellence Inside CAR T manufacturing Industry Theatre- Gilead.mp4
Mar 22 Lymphomas.mp4
Mar 22 MDS MPN SAA.mp4
Mar 22 Optimisation of transplant outcome by modifiable pre- and peri-transplant variables.mp4
Mar 22 Oral session 4 Infectious complications I.mp4
Mar 22 Oral session 5 Non-infectious early and late complications.mp4
Mar 22 Oral session 6 Infectious complications II, COVID.mp4
Mar 22 Oral session 7 MRD, chimerism, relapse, and immune reconstitution.mp4
Mar 22 Oral session 8 CAR-T I.mp4
Mar 22 Oral session 9 Cellular therapies other than CARs, cell-based immune therapies, stem cell engineering.mp4
Mar 22 Paediatric Diseases Oral Session.mp4
Mar 22 Paediatrics Diseases Working Party Session.mp4
Mar 22 Paediatrics Session Communication challenges in paediatric HSCT nursing.mp4
Mar 22 Prophylaxis versus diagnostic-driven therapy Best-practice approaches for treating IMD in haematology patients Pfizer Industry Symposium.mp4
Mar 22 Research sesslon 1 Best nursmg research abstracts.mp4
Mar 22 State of the art update for managing patients with relapsed refractory (RRMM) multiple myeloma and future potential of cellular therapies Janssen Industry Symposium.mp4
Mar 22 Statistical Symposium.mp4
Mar 22 Transplant Complications Working Party session.mp4
Mar 23 CAR T.mp4
Mar 23 Closing Session.mp4
Mar 23 CMV still a challenge.mp4
Mar 23 How do I manage… Palliative care and advanced care planning.mp4
Mar 23 Joint session EBMT-EHA Academical clinical trials in Europe.mp4
Mar 23 Lymphoma Working Party session.mp4
Mar 23 Modulation of microbiome pre-, peri- and post-transplant – is it time to become routine practice.mp4
Mar 23 Multi-stakeholder Forum on Innovative Cellular Therapies 2 Innovative Therapies from bench to bedside.mp4
Mar 23 New developments in CAR T cell therapy.mp4
Mar 23 Novel insights into systemic hyperinflammation syndromes.mp4
Mar 23 Nurses Programme Closing Session.mp4
Mar 23 Oral session 10 GVHD I, clinical.mp4
Mar 23 Oral session 11 Aplastic anemia, autoimmune diseases.mp4
Mar 23 Oral session 12 Acute leukemia.mp4
Mar 23 Oral session 13 CAR-T II.mp4
Mar 23 Oral session 14 GVHD II, clinical and preclinical.mp4
Mar 23 Oral session 15 New drugs, gene therapy and experimental transplantation.mp4
Mar 23 Oral session 16 Conditioning.mp4
Mar 23 Oral session 17 Stem cell donor, stem cell source, mobilisation and collection.mp4
Mar 23 Oral session 18 Paediatrics.mp4
Mar 23 Oral session 19 Non-infectious late effects and complications.mp4
Mar 23 Severe Aplastic Anaemia Working Party session.mp4
Mar 23 Survivorship beyond survival.mp4
Mar 23 Update on viral infections in the transplant setting.mp4
pdf-program.pdf
Reviews
There are no reviews yet.